Abstract
Biological therapies have transformed the management of psoriasis, but clinical response is variable and there is an unmet clinical need to identify predictive biomarkers. Whilst newer biologics have been licensed, the anti-TNF drug adalimumab remains a first-line intervention in psoriasis, given its effectiveness, well-established safety profile and, with the advent of biosimilars, significantly reduced costs. Nevertheless, the cellular and molecular mechanisms underpinning its clinical efficacy are ill understood and no companion diagnostic exists to guide prescription.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
